Sulbactam combined with tigecycline improves outcomes in patients with severe multidrug-resistant Acinetobacter baumannii pneumonia
Background The purpose of this study was to review the treatment plan of patients with multidrug-resistant Acinetobacter baumannii (MDR-AB) pneumonia and analyze the factors associated with patient deaths and the medication regimen. Methods We collected 1,823 qualified respiratory specimens that wer...
Saved in:
| Published in | BMC infectious diseases Vol. 22; no. 1; pp. 795 - 8 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
21.10.2022
BioMed Central Ltd BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1471-2334 1471-2334 |
| DOI | 10.1186/s12879-022-07778-5 |
Cover
Loading…
| Abstract | Background
The purpose of this study was to review the treatment plan of patients with multidrug-resistant
Acinetobacter baumannii
(MDR-AB) pneumonia and analyze the factors associated with patient deaths and the medication regimen.
Methods
We collected 1,823 qualified respiratory specimens that were culture-positive for MDR-AB. 166 patients confirmed to have hospital-acquired MDR-AB pneumonia were selected as the research subjects. The differing clinical characteristics and treatment interventions between the surviving group and death group within 28 days were analyzed.
Results
The mortality rate was high for those aged > 75 years (
p
= 0.001). Patients who underwent invasive catheter placement (
p
< 0.001) and mechanical ventilation (
p
= 0.046) had a higher mortality rate. Combination therapy with tigecycline can reduce the mortality rate (
p
< 0.001) of MDR-AB pneumonia in patients with carbapenem-resistant AB(CRAB). Combination therapy with sulbactam was shown to reduce the mortality rate (
p
< 0.001), and high-dose sulbactam (> 3 g/day) might be better than low-dose sulbactam (≤ 3 g/day).
Conclusion
Reducing the time of invasive catheter placement and mechanical ventilation in patients in the intensive care unit (ICU), antimicrobial treatment, combined with tigecycline and sulbactam, might help reduce the mortality rate in patients with severe MDR-AB hospital-acquired pneumonia. |
|---|---|
| AbstractList | Abstract Background The purpose of this study was to review the treatment plan of patients with multidrug-resistant Acinetobacter baumannii (MDR-AB) pneumonia and analyze the factors associated with patient deaths and the medication regimen. Methods We collected 1,823 qualified respiratory specimens that were culture-positive for MDR-AB. 166 patients confirmed to have hospital-acquired MDR-AB pneumonia were selected as the research subjects. The differing clinical characteristics and treatment interventions between the surviving group and death group within 28 days were analyzed. Results The mortality rate was high for those aged > 75 years (p = 0.001). Patients who underwent invasive catheter placement (p < 0.001) and mechanical ventilation (p = 0.046) had a higher mortality rate. Combination therapy with tigecycline can reduce the mortality rate (p < 0.001) of MDR-AB pneumonia in patients with carbapenem-resistant AB(CRAB). Combination therapy with sulbactam was shown to reduce the mortality rate (p < 0.001), and high-dose sulbactam (> 3 g/day) might be better than low-dose sulbactam (≤ 3 g/day). Conclusion Reducing the time of invasive catheter placement and mechanical ventilation in patients in the intensive care unit (ICU), antimicrobial treatment, combined with tigecycline and sulbactam, might help reduce the mortality rate in patients with severe MDR-AB hospital-acquired pneumonia. The purpose of this study was to review the treatment plan of patients with multidrug-resistant Acinetobacter baumannii (MDR-AB) pneumonia and analyze the factors associated with patient deaths and the medication regimen.BACKGROUNDThe purpose of this study was to review the treatment plan of patients with multidrug-resistant Acinetobacter baumannii (MDR-AB) pneumonia and analyze the factors associated with patient deaths and the medication regimen.We collected 1,823 qualified respiratory specimens that were culture-positive for MDR-AB. 166 patients confirmed to have hospital-acquired MDR-AB pneumonia were selected as the research subjects. The differing clinical characteristics and treatment interventions between the surviving group and death group within 28 days were analyzed.METHODSWe collected 1,823 qualified respiratory specimens that were culture-positive for MDR-AB. 166 patients confirmed to have hospital-acquired MDR-AB pneumonia were selected as the research subjects. The differing clinical characteristics and treatment interventions between the surviving group and death group within 28 days were analyzed.The mortality rate was high for those aged > 75 years (p = 0.001). Patients who underwent invasive catheter placement (p < 0.001) and mechanical ventilation (p = 0.046) had a higher mortality rate. Combination therapy with tigecycline can reduce the mortality rate (p < 0.001) of MDR-AB pneumonia in patients with carbapenem-resistant AB(CRAB). Combination therapy with sulbactam was shown to reduce the mortality rate (p < 0.001), and high-dose sulbactam (> 3 g/day) might be better than low-dose sulbactam (≤ 3 g/day).RESULTSThe mortality rate was high for those aged > 75 years (p = 0.001). Patients who underwent invasive catheter placement (p < 0.001) and mechanical ventilation (p = 0.046) had a higher mortality rate. Combination therapy with tigecycline can reduce the mortality rate (p < 0.001) of MDR-AB pneumonia in patients with carbapenem-resistant AB(CRAB). Combination therapy with sulbactam was shown to reduce the mortality rate (p < 0.001), and high-dose sulbactam (> 3 g/day) might be better than low-dose sulbactam (≤ 3 g/day).Reducing the time of invasive catheter placement and mechanical ventilation in patients in the intensive care unit (ICU), antimicrobial treatment, combined with tigecycline and sulbactam, might help reduce the mortality rate in patients with severe MDR-AB hospital-acquired pneumonia.CONCLUSIONReducing the time of invasive catheter placement and mechanical ventilation in patients in the intensive care unit (ICU), antimicrobial treatment, combined with tigecycline and sulbactam, might help reduce the mortality rate in patients with severe MDR-AB hospital-acquired pneumonia. The purpose of this study was to review the treatment plan of patients with multidrug-resistant Acinetobacter baumannii (MDR-AB) pneumonia and analyze the factors associated with patient deaths and the medication regimen. We collected 1,823 qualified respiratory specimens that were culture-positive for MDR-AB. 166 patients confirmed to have hospital-acquired MDR-AB pneumonia were selected as the research subjects. The differing clinical characteristics and treatment interventions between the surviving group and death group within 28 days were analyzed. The mortality rate was high for those aged > 75 years (p = 0.001). Patients who underwent invasive catheter placement (p < 0.001) and mechanical ventilation (p = 0.046) had a higher mortality rate. Combination therapy with tigecycline can reduce the mortality rate (p < 0.001) of MDR-AB pneumonia in patients with carbapenem-resistant AB(CRAB). Combination therapy with sulbactam was shown to reduce the mortality rate (p < 0.001), and high-dose sulbactam (> 3 g/day) might be better than low-dose sulbactam ([less than or equai to] 3 g/day). Reducing the time of invasive catheter placement and mechanical ventilation in patients in the intensive care unit (ICU), antimicrobial treatment, combined with tigecycline and sulbactam, might help reduce the mortality rate in patients with severe MDR-AB hospital-acquired pneumonia. The purpose of this study was to review the treatment plan of patients with multidrug-resistant Acinetobacter baumannii (MDR-AB) pneumonia and analyze the factors associated with patient deaths and the medication regimen. We collected 1,823 qualified respiratory specimens that were culture-positive for MDR-AB. 166 patients confirmed to have hospital-acquired MDR-AB pneumonia were selected as the research subjects. The differing clinical characteristics and treatment interventions between the surviving group and death group within 28 days were analyzed. The mortality rate was high for those aged > 75 years (p = 0.001). Patients who underwent invasive catheter placement (p < 0.001) and mechanical ventilation (p = 0.046) had a higher mortality rate. Combination therapy with tigecycline can reduce the mortality rate (p < 0.001) of MDR-AB pneumonia in patients with carbapenem-resistant AB(CRAB). Combination therapy with sulbactam was shown to reduce the mortality rate (p < 0.001), and high-dose sulbactam (> 3 g/day) might be better than low-dose sulbactam (≤ 3 g/day). Reducing the time of invasive catheter placement and mechanical ventilation in patients in the intensive care unit (ICU), antimicrobial treatment, combined with tigecycline and sulbactam, might help reduce the mortality rate in patients with severe MDR-AB hospital-acquired pneumonia. Background The purpose of this study was to review the treatment plan of patients with multidrug-resistant Acinetobacter baumannii (MDR-AB) pneumonia and analyze the factors associated with patient deaths and the medication regimen. Methods We collected 1,823 qualified respiratory specimens that were culture-positive for MDR-AB. 166 patients confirmed to have hospital-acquired MDR-AB pneumonia were selected as the research subjects. The differing clinical characteristics and treatment interventions between the surviving group and death group within 28 days were analyzed. Results The mortality rate was high for those aged > 75 years ( p = 0.001). Patients who underwent invasive catheter placement ( p < 0.001) and mechanical ventilation ( p = 0.046) had a higher mortality rate. Combination therapy with tigecycline can reduce the mortality rate ( p < 0.001) of MDR-AB pneumonia in patients with carbapenem-resistant AB(CRAB). Combination therapy with sulbactam was shown to reduce the mortality rate ( p < 0.001), and high-dose sulbactam (> 3 g/day) might be better than low-dose sulbactam (≤ 3 g/day). Conclusion Reducing the time of invasive catheter placement and mechanical ventilation in patients in the intensive care unit (ICU), antimicrobial treatment, combined with tigecycline and sulbactam, might help reduce the mortality rate in patients with severe MDR-AB hospital-acquired pneumonia. Background The purpose of this study was to review the treatment plan of patients with multidrug-resistant Acinetobacter baumannii (MDR-AB) pneumonia and analyze the factors associated with patient deaths and the medication regimen. Methods We collected 1,823 qualified respiratory specimens that were culture-positive for MDR-AB. 166 patients confirmed to have hospital-acquired MDR-AB pneumonia were selected as the research subjects. The differing clinical characteristics and treatment interventions between the surviving group and death group within 28 days were analyzed. Results The mortality rate was high for those aged > 75 years (p = 0.001). Patients who underwent invasive catheter placement (p < 0.001) and mechanical ventilation (p = 0.046) had a higher mortality rate. Combination therapy with tigecycline can reduce the mortality rate (p < 0.001) of MDR-AB pneumonia in patients with carbapenem-resistant AB(CRAB). Combination therapy with sulbactam was shown to reduce the mortality rate (p < 0.001), and high-dose sulbactam (> 3 g/day) might be better than low-dose sulbactam (≤ 3 g/day). Conclusion Reducing the time of invasive catheter placement and mechanical ventilation in patients in the intensive care unit (ICU), antimicrobial treatment, combined with tigecycline and sulbactam, might help reduce the mortality rate in patients with severe MDR-AB hospital-acquired pneumonia. Background The purpose of this study was to review the treatment plan of patients with multidrug-resistant Acinetobacter baumannii (MDR-AB) pneumonia and analyze the factors associated with patient deaths and the medication regimen. Methods We collected 1,823 qualified respiratory specimens that were culture-positive for MDR-AB. 166 patients confirmed to have hospital-acquired MDR-AB pneumonia were selected as the research subjects. The differing clinical characteristics and treatment interventions between the surviving group and death group within 28 days were analyzed. Results The mortality rate was high for those aged > 75 years (p = 0.001). Patients who underwent invasive catheter placement (p < 0.001) and mechanical ventilation (p = 0.046) had a higher mortality rate. Combination therapy with tigecycline can reduce the mortality rate (p < 0.001) of MDR-AB pneumonia in patients with carbapenem-resistant AB(CRAB). Combination therapy with sulbactam was shown to reduce the mortality rate (p < 0.001), and high-dose sulbactam (> 3 g/day) might be better than low-dose sulbactam ([less than or equai to] 3 g/day). Conclusion Reducing the time of invasive catheter placement and mechanical ventilation in patients in the intensive care unit (ICU), antimicrobial treatment, combined with tigecycline and sulbactam, might help reduce the mortality rate in patients with severe MDR-AB hospital-acquired pneumonia. Keywords: Multi-drug resistant Acinetobacter baumannii (MDR-AB), Carbapenem-resistant Acinetobacter baumannii(CRAB), Severe pneumonia, Intensive care unit |
| ArticleNumber | 795 |
| Audience | Academic |
| Author | Deng, Yanling Yue, Mingrui Huang, Xiaobo Yu, Hua Yang, Yang Chen, Lin |
| Author_xml | – sequence: 1 givenname: Yanling surname: Deng fullname: Deng, Yanling organization: Department of Respiratory and Critical Care Medicine, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China – sequence: 2 givenname: Lin surname: Chen fullname: Chen, Lin email: chenlinhx@med.uestc.edu.cn organization: Department of Respiratory and Critical Care Medicine, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital – sequence: 3 givenname: Mingrui surname: Yue fullname: Yue, Mingrui organization: Department of Intensive Care Unit, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital – sequence: 4 givenname: Xiaobo surname: Huang fullname: Huang, Xiaobo organization: Department of Intensive Care Unit, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital – sequence: 5 givenname: Yang surname: Yang fullname: Yang, Yang organization: Department of Respiratory and Critical Care Medicine, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital – sequence: 6 givenname: Hua surname: Yu fullname: Yu, Hua organization: Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Department of Laboratory Medcine, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36271362$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkktr3DAUhU1JaZJp_0AXxdBNu3Cqh2XJm8IQ-hgIBJq2WyHL144GW5pK8rRZ949XE6dJJpRQDLa4_s65-PgcZwfWWciylxidYCyqdwETwesCEVIgzrko2JPsCJccF4TS8uDe-TA7DmGNEOaC1M-yQ1oRjtPtKPt9MQ2N0lGNuXZjYyy0-U8TL_NoetBXekiT3Iwb77YQcjfFRKWDsflGRQM2hhkPsAUP-TgN0bR-6gsPwYSobMyXOnlEt9sCPm_UNCprjck3FqbRWaOeZ087NQR4cfNcZN8-fvh6-rk4O_-0Ol2eFZrViBUUiGaoqjCpKtJ1DOmOd1xAXZeASCOgbXXJtEYdMNZW0GABgEmDeVlXSGC6yFazb-vUWm68GZW_kk4ZeT1wvpfKR6MHkKVAqMYCUS1ISSrdAKi0toauwR1iTfJ6P3ttpmaEVqckvBr2TPffWHMpe7eVNROMM5IM3twYePdjghDlaIKGYVAW3BQk4YRXZUkZSujrB-jaTd6mqBJFeVULStkd1av0AcZ2Lu3VO1O55IRyhEiyW2Qn_6DS1cJodOpXZ9J8T_B2T5CYCL9ir6YQ5Oriy_-z59_32Vf3A7xN7m81E0BmQHsXgofuFsFI7vov5_7L1H953X-5C0E8EGkTU1Hd7ieY4XEpnaUh7bE9-LuUH1H9AQ3vGYw |
| CitedBy_id | crossref_primary_10_1007_s10096_023_04583_z crossref_primary_10_3390_antibiotics13090907 crossref_primary_10_3390_futurepharmacol3020030 crossref_primary_10_37489_0235_2990_2024_69_7_8_53_66 crossref_primary_10_1002_hsr2_70066 crossref_primary_10_3389_fcimb_2024_1289396 crossref_primary_10_1186_s12879_023_08715_w crossref_primary_10_3389_fmicb_2023_1217270 crossref_primary_10_36488_cmac_2023_1_41_55 crossref_primary_10_1097_MJT_0000000000001934 crossref_primary_10_2478_pneum_2024_0020 crossref_primary_10_56712_latam_v6i1_3409 |
| Cites_doi | 10.3760/cma.j.issn.1001-0939.2018.04.006 10.1038/nrmicro1789 10.1016/j.ejps.2019.05.018 10.5414/cp202557 10.1097/ccm.0000000000000933 10.1016/j.ijantimicag.2015.11.011 10.1186/1471-2334-14-102 10.1111/jam.15130 10.1093/jac/dkh080 10.3390/antibiotics9030119 10.2147/IDR.S166750 10.1186/s12879-017-2932-5 10.1007/s11908-019-0706-5 10.13286/j.cnki.chinhosppharmacyj.2019.07.05 10.1080/00365540600951184 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2022 2022. The Author(s). COPYRIGHT 2022 BioMed Central Ltd. 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2022 – notice: 2022. The Author(s). – notice: COPYRIGHT 2022 BioMed Central Ltd. – notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QL 7T2 7U9 7X7 7XB 88E 8C1 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BENPR C1K CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P M7N PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM DOA |
| DOI | 10.1186/s12879-022-07778-5 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Opposing Viewpoints in Context (Gale) Gale In Context: Science ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Health and Safety Science Abstracts (Full archive) Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability (subscription) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Environmental Sciences and Pollution Management ProQuest Central ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection AIDS and Cancer Research Abstracts Health & Safety Science Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2334 |
| EndPage | 8 |
| ExternalDocumentID | oai_doaj_org_article_480091803c82426cbeea2669efb1f05b PMC9585752 A723700244 36271362 10_1186_s12879_022_07778_5 |
| Genre | Journal Article |
| GeographicLocations | China |
| GeographicLocations_xml | – name: China |
| GrantInformation_xml | – fundername: Department of Science and Technology of Sichuan Province grantid: 2021YFS0373 funderid: http://dx.doi.org/10.13039/501100004829 – fundername: Department of Science and Technology of Sichuan Province grantid: 2021YFS0373 – fundername: ; grantid: 2021YFS0373 |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8C1 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR IOV ISR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB AAYXX ALIPV CITATION CGR CUY CVF ECM EIF NPM PMFND 3V. 7QL 7T2 7U9 7XB 8FK AZQEC C1K DWQXO H94 K9. M7N PKEHL PQEST PQUKI 7X8 5PM |
| ID | FETCH-LOGICAL-c5905-3e2c506612662ff50cf7f78e994e02b8eddc45cc0fe55d6eb18ee12b174960813 |
| IEDL.DBID | M48 |
| ISSN | 1471-2334 |
| IngestDate | Wed Aug 27 01:24:30 EDT 2025 Thu Aug 21 18:39:40 EDT 2025 Fri Sep 05 07:25:18 EDT 2025 Sat Sep 06 22:11:38 EDT 2025 Tue Jun 17 21:09:21 EDT 2025 Tue Jun 10 20:31:40 EDT 2025 Fri Jun 27 04:38:34 EDT 2025 Fri Jun 27 04:19:01 EDT 2025 Mon Jul 21 06:07:59 EDT 2025 Thu Apr 24 23:00:57 EDT 2025 Tue Jul 01 03:10:40 EDT 2025 Sat Sep 06 07:26:49 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Multi-drug resistant Carbapenem-resistant MDR-AB Severe pneumonia Intensive care unit CRAB Carbapenem-resistant Acinetobacter baumannii(CRAB) Multi-drug resistant Acinetobacter baumannii (MDR-AB) |
| Language | English |
| License | 2022. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5905-3e2c506612662ff50cf7f78e994e02b8eddc45cc0fe55d6eb18ee12b174960813 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12879-022-07778-5 |
| PMID | 36271362 |
| PQID | 2737698335 |
| PQPubID | 42582 |
| PageCount | 8 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_480091803c82426cbeea2669efb1f05b pubmedcentral_primary_oai_pubmedcentral_nih_gov_9585752 proquest_miscellaneous_2727644350 proquest_journals_2737698335 gale_infotracmisc_A723700244 gale_infotracacademiconefile_A723700244 gale_incontextgauss_ISR_A723700244 gale_incontextgauss_IOV_A723700244 pubmed_primary_36271362 crossref_primary_10_1186_s12879_022_07778_5 crossref_citationtrail_10_1186_s12879_022_07778_5 springer_journals_10_1186_s12879_022_07778_5 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20221021 |
| PublicationDateYYYYMMDD | 2022-10-21 |
| PublicationDate_xml | – month: 10 year: 2022 text: 20221021 day: 21 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | BMC infectious diseases |
| PublicationTitleAbbrev | BMC Infect Dis |
| PublicationTitleAlternate | BMC Infect Dis |
| PublicationYear | 2022 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | B Chen (7778_CR4) 2012; 2 A Cheng (7778_CR12) 2015; 43 C Ayoub Moubareck (7778_CR2) 2020; 9 AP Betrosian (7778_CR17) 2007; 39 YC Chuang (7778_CR7) 2014; 14 Infectology Group of Respiratory Diseases Branch of Chinese Medical Association (CMA) (7778_CR8) 2018; 41 J Li (7778_CR15) 2019; 39 M Asif (7778_CR3) 2018; 11 M Nguyen (7778_CR13) 2021; 131 S Jaruratanasirikul (7778_CR16) 2019; 136 H Huang (7778_CR9) 2018; 18 W Ni (7778_CR11) 2016; 47 7778_CR6 7778_CR5 L Dijkshoorn (7778_CR1) 2007; 5 P Li (7778_CR10) 2017; 55 WC Ko (7778_CR14) 2004; 53 |
| References_xml | – volume: 41 start-page: 255 year: 2018 ident: 7778_CR8 publication-title: Chin J Tuberc Respir Dis doi: 10.3760/cma.j.issn.1001-0939.2018.04.006 – volume: 2 start-page: 3 year: 2012 ident: 7778_CR4 publication-title: China Med Pharm – volume: 5 start-page: 939 year: 2007 ident: 7778_CR1 publication-title: Nat Rev Microbiol doi: 10.1038/nrmicro1789 – volume: 136 start-page: 104940 year: 2019 ident: 7778_CR16 publication-title: Eur J Pharm Sci doi: 10.1016/j.ejps.2019.05.018 – volume: 55 start-page: 588 year: 2017 ident: 7778_CR10 publication-title: Int J Clin Pharmacol Ther doi: 10.5414/cp202557 – volume: 43 start-page: 1194 year: 2015 ident: 7778_CR12 publication-title: Crit Care Med doi: 10.1097/ccm.0000000000000933 – volume: 47 start-page: 107 year: 2016 ident: 7778_CR11 publication-title: Int J Antimicrob Agents doi: 10.1016/j.ijantimicag.2015.11.011 – ident: 7778_CR6 – volume: 14 start-page: 102 year: 2014 ident: 7778_CR7 publication-title: BMC Infect Dis doi: 10.1186/1471-2334-14-102 – volume: 131 start-page: 2715 year: 2021 ident: 7778_CR13 publication-title: J Appl Microbiol doi: 10.1111/jam.15130 – volume: 53 start-page: 393 year: 2004 ident: 7778_CR14 publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkh080 – volume: 9 start-page: 119 year: 2020 ident: 7778_CR2 publication-title: Antibiotics doi: 10.3390/antibiotics9030119 – volume: 11 start-page: 1249 year: 2018 ident: 7778_CR3 publication-title: Infect Drug Resist doi: 10.2147/IDR.S166750 – volume: 18 start-page: 11 year: 2018 ident: 7778_CR9 publication-title: BMC Infect Dis doi: 10.1186/s12879-017-2932-5 – ident: 7778_CR5 doi: 10.1007/s11908-019-0706-5 – volume: 39 start-page: 676 year: 2019 ident: 7778_CR15 publication-title: Chin J Hosp Pharm doi: 10.13286/j.cnki.chinhosppharmacyj.2019.07.05 – volume: 39 start-page: 38 year: 2007 ident: 7778_CR17 publication-title: Scand J Infect Dis doi: 10.1080/00365540600951184 |
| SSID | ssj0017829 |
| Score | 2.3664987 |
| Snippet | Background
The purpose of this study was to review the treatment plan of patients with multidrug-resistant
Acinetobacter baumannii
(MDR-AB) pneumonia and... The purpose of this study was to review the treatment plan of patients with multidrug-resistant Acinetobacter baumannii (MDR-AB) pneumonia and analyze the... Background The purpose of this study was to review the treatment plan of patients with multidrug-resistant Acinetobacter baumannii (MDR-AB) pneumonia and... Abstract Background The purpose of this study was to review the treatment plan of patients with multidrug-resistant Acinetobacter baumannii (MDR-AB) pneumonia... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 795 |
| SubjectTerms | Acinetobacter baumannii Acinetobacter Infections - drug therapy Anti-Bacterial Agents - pharmacology Anti-Infective Agents - therapeutic use Antibiotics Antiinfectives and antibacterials Bacterial pneumonia Carbapenem-resistant Acinetobacter baumannii(CRAB) Carbapenems - therapeutic use Catheters Causes of Dosage and administration Drug dosages Drug resistance Drug Resistance, Multiple, Bacterial Drug therapy Humans Infectious Diseases Intensive care unit Internal Medicine Intubation Laboratories Mechanical ventilation Medical instruments Medical Microbiology Medical prognosis Medicine Medicine & Public Health Microbial Sensitivity Tests Mortality Multi-drug resistant Acinetobacter baumannii (MDR-AB) Multidrug resistance Multidrug resistant organisms Normal distribution Nosocomial infections Parasitology Patient outcomes Patients Placement Pneumonia Pneumonia - drug therapy Retrospective Studies Severe pneumonia Sulbactam Sulbactam - therapeutic use Tigecycline Tigecycline - pharmacology Tropical Medicine Ventilation Ventilators |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gLojwDBRmExAGiOlk7jo8LoipIBYlS1JsVO-MlUslWm-TQM3-cmTyWpqhw4bK7Wo-12ZnxzDee8Zixl0p4wrV5LL0LsQw6xCYVOi7plpMC47HQb-YcfcoOT-THU3V66aovqgkb2gMPjNuXiGhMkouFz8mbeAdQoFMxEFwShHJkfYURUzA15g_Q75npiEye7TdohbWJqXJdaI1xk5q5ob5b_582-ZJTuloweSVr2jujgzvs9ogi-XJ4-l12A-q77ObRmCe_x34ed2eu8G3xg6NGYfALJacdV95WK_AXdBwSeNXvJ0DD112LVPihqvnYZ7UZyNFtwgZ4X3VYbrpVjME5Ac665Uv6JbIG1O2Zu4KSAXVV8fMaOlTtqrjPTg7ef313GI_XLcReGcqHQ-oVIpAE2ZuGgFJEyekcjJEgUpdDWXqpvBcBlCozNPI5QJI6jGkwDMqTxQO2U69reMS4VCZzGDkaL1MJDt-NkhpnC5frkMmIJRP3rR97kdOVGGe2j0nyzA4Ssygx20vMqoi93s45Hzpx_JX6LQl1S0ldtPsvULfsqFv2X7oVsRekEpb6ZNRUiLMquqaxHz5_s0udLjQBHHkd0fGXGdGrkSis8Y_6Yjz8gOyi_lszyr0ZJa52Px-e1NOO1qaxCEF1Zuj4XMSeb4dpJlXQ1bDuiCbViH0XSkTs4aDNW-YgiNEJvkRMz_R8xr35SF1973uRG0VXvOLMN9OK-P1Y10vn8f-QzhN2K6UVjUAiTfbYTrvp4CkixNY9643BL-ITYKw priority: 102 providerName: Directory of Open Access Journals – databaseName: Public Health Database dbid: 8C1 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdgSIgXxDeBgQxC4gGiJakd20-oTEwDaSAxhvZmxY5dIo2kNMkDz_zj3LluR4a2lzSqz2rt8939zj7fEfKKZxZxrUyZNT5lXvhUFZlIa6xyUoE_5sNmztHn8vCEfTrlp3HDrY9hlRudGBR13VncI98DMytKhVeE3i1_pVg1Ck9XYwmN6-RGDjoYBVPub0M8crB-anNRRpZ7PehioVKMX8-EAO-JT4xRyNn_v2b-xzRdDJu8cHYaTNLBHXI7Ykk6XzP_Lrnm2nvk5lE8Lb9P_hyPZ6ayQ_WTwhjBBXY1xX1XOjQLZ3_jpUhHm7Cr4HrajQNQwUvT0phttV-Tg_F0K0dD7GG9GhcpuOgIO9uBzvGXUCdgzmdqKjwSaJuGLls3wow11QNycvDh2_5hGosupJYrPBV3heWAQ3Kw3IX3wEvgn5BOKeaywkhX15ZxazPvOK9LUPXSubww4NmAMyTz2UOy03ate0wo46o04D8qywrmDHwqzgT0zowUvmQJyTezr23MSI6FMc508Exkqdcc08AxHTimeULebPss1_k4rqR-j0zdUmIu7fBFt1roKJqaAWZWucxmViJesca5CgavnDe5z7hJyEtcEhqzZbQYjrOoxr7XH79813NRzATCHHYZ0fHXCdHrSOQ7GKit4hUImC7MwjWh3J1QgszbafNmeeqoc3p9LiEJebFtxp4YR9e6bkSaQgACnvEsIY_Wq3k7OQBlRA6PhIjJOp_M3rSlbX6EjOSKY6FX6Pl2IxHnf-ty7jy5ehRPya0CZRWAQpHvkp1hNbpngAAH8zyI-V_jVVhV priority: 102 providerName: ProQuest – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3fb9MwELZgSIgXxG8CAxmExANEJK4dx49lYhpIA4kxtDcrds4l0kinJnngmX-cOzcty2BIPLWqP6uJ7873nc8-M_ZCZZ54bZlK70Iqgw6pEZlOa7rlpMJ4LMTFnMOPxcGx_HCiTsYyOXQW5nz-Pi-LNx3On9qktOc80xojHnWVXVP5rIiJ2WJvmzFAT2c2h2L-2m_ieGJ9_j9n4XNu6OIWyQt50uh-9m-xmyNv5PO1oG-zK9DeYdcPx8z4XfbzaDh1le-r7xx1CMNdqDmtsfK-WYD_QQcggTdxBQE6vhx6ROGXpuVjZdVuDUdHCSvgcZ9hvRoWKYbjRDHbns_pn8j-qb4zdxUt_7dNw89aGFCZm-oeO95_92XvIB0vWEi9MpQBB-EVco4cvbQIAeWGstIlGCMhE66EuvZSeZ8FUKoucFovAXLhMIrBwKfMZ_fZTrts4SHjUpnCYaxovBQSHH4aJTX2zlypQyETlm9G3_qx-jhdgnFqYxRSFnYtMYsSs1FiViXs1bbP2br2xj_Rb0moWyTVzY4_oDrZ0QytRH5s8jKb-ZK4iXcAFb68geDykCmXsOekEpYqY7S09WZRDV1n33_6audazDRRGnkZ6OjzBPRyBIUlvqivxuMOOFxUcWuC3J0g0b79tHmjnnacXzqLpFMXhg7MJezZtpl60p65FpYDYYRGtjtTWcIerLV5OzhIWzQakUiYnuj5ZPSmLW3zLVYfN4oudcWerzcW8fuxLpfOo_-DP2Y3BNkukgSR77KdfjXAE2R_vXsazf4XP2hRgg priority: 102 providerName: Springer Nature |
| Title | Sulbactam combined with tigecycline improves outcomes in patients with severe multidrug-resistant Acinetobacter baumannii pneumonia |
| URI | https://link.springer.com/article/10.1186/s12879-022-07778-5 https://www.ncbi.nlm.nih.gov/pubmed/36271362 https://www.proquest.com/docview/2737698335 https://www.proquest.com/docview/2727644350 https://pubmed.ncbi.nlm.nih.gov/PMC9585752 https://doaj.org/article/480091803c82426cbeea2669efb1f05b |
| Volume | 22 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bb9MwFLZ2kRAviDuBURmExAOEJakdxw8ItdWmgdSBOoomXqzYcUqkko42kdgzf5xz3KQjY-OJF_fiY7XxuX3Hl3MIecEDg7g28ZnRuc9ykfsyCoSfYZWTFOKx3C3mjI_joyn7cMpPt0hb7qiZwNWVoR3Wk5ou529-_jh_Bwr_1il8Eu-vwMYK6eO59EAIiIr4NtkFzxRjMDZmF7sK4A1le3HmynEd5-Ry-P9tqf9wVZePUV7aS3Uu6vA2udVgSzpYC8MdsmXLu-TGuNk9v0d-ndRznZoq_U5BziAkthnFdVhaFTNrzvGSpKWFW2WwK7qoK6CCN0VJm-yrqzU5OFO7tNSdRcyW9cyHkB1haFnRAf4S2gjMAU11ilsEZVHQs9LWIPBFep9MDw8-j478pgiDb7jEXXIbGQ64JARPHuU58Bb4KRIrJbNBpBObZYZxY4Lccp7FYPoTa8NIQ6QDwVES9h-QnXJR2keEMi5jDfGkNCxiVsOr5EzA6EAnIo-ZR8J29pVpMpRjoYy5cpFKEqs1xxRwTDmOKe6RV5sxZ-v8HP-kHiJTN5SYW9t9sVjOVKOqigGGlmES9E2C-MVoa1N4eGlzHeYB1x55jiKhMHtGicdzZmm9Wqn3H7-ogYj6AmEPu47oZNIhetkQ5Qt4UJM2VyJgujArV4dyr0MJNsB0u1vxVK0KKQCmIpZ4qc4jzzbdOBLP1ZV2USNNJAAR93ngkYdrad5MDkAbEULjEdGR887sdXvK4pvLUC45Fn6Fka9bjbj4W9dz5_H_4M4TcjNCjQZ4EYV7ZKda1vYp4MZK98i2OBXQJqOwR3aHB8efJvBpFI96biWm54wFtJPh199VBG7L |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfGkIAXxDeBAQaBeIBoiWvH8QNC5WNa2ToktqG-mcRxSqSRlCYR2jP_D38jd_noyND2tpe2as6t7Tvf_c4-3xHyXHgGcW3ochOnLk9l6irmSTfBKicR-GNps5kz3Qu2D_mnmZitkT_9XRgMq-x1YqOok8LgHvkmmFkZKLwi9Hbx08WqUXi62pfQaMVixx7_ApetfDP5APx9wdjWx4P3225XVcA1QuGxr2VGgKH1wTSxNIXOQgdlaJXi1mNxaJPEcGGMl1ohkgB0WWitz2KA7oD2Q38Ev3uJXOa4Mw7rR85WDp4P1lb1F3PCYLME3S-Vi_HynpTgrYmB8WtqBPxvCf4xhafDNE-d1TYmcOsGud5hVzpuhe0mWbP5LXJl2p3O3ya_9-ujODJV9IPCnILLbROK-7y0yubWHOMlTEuzZhfDlrSoK6CCD1lOu-yuZUsOxtouLW1iHZNlPXeXtkSYm1d0jP-EOghzTNM4wiOIPMvoIrc1cCiL7pDDC2HHXbKeF7m9TygXKojBX1WGM25jeFeCS2jtxaFMA-4Qv599bboM6FiI40g3nlAY6JZjGjimG45p4ZBXqzaLNv_HudTvkKkrSszd3XxRLOe6UwWaA0ZXfuiNTIj4yMTWRjB4ZdPYTz0RO-QZioTG7Bw5hv_Mo7os9eTzVz2WbCQRVvGziPa_DIhedkRpAQM1UXflAqYLs34NKDcGlKBjzPBxL56603GlPlmRDnm6eowtMW4vt0WNNEwC4h4JzyH3WmleTQ5AJ-nDi0PkQM4Hszd8kmffmwzoSmBhWWj5ul8RJ906mzsPzh_FE3J1-2C6q3cnezsPyTWG6xZACvM3yHq1rO0jQJ9V_LhZ8pR8u2gd8xfjmpTT |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELdgSBMviO8FBhiExANES1I7jh_LYNqADcQY2psVO3aJNNyqSR545h_nzknLMhgSL2lUn9XaZ9_9zvdhQp7zxCCuLWJmtIuZEy6WWSLiCm85KcEec-Ew5_Ao3z9h70756bks_hDtvnJJ9jkNWKXJtzuLyvVbvMh3GpCqQsYYiZ4IAXYQv0quMVR96K7Nd9d-BNB_cpUq89d-I3UUqvb_KZvPKaeLgZMXvKdBKe3dJDcGNEmnPftvkSvW3yabh4O__A75edyd6dK05XcKgwQj2FYUT15pW8-s-YFpkZbW4VzBNnTetUAFL7WnQ73VpicH9WmXlobow2rZzWIw0hF4-pZO8ZdQKmDVZ6pLdAr4uqYLbztY4nV5l5zsvf2yux8P1y7Ehkv0i9vMcEAiKejuzDngJnBQFFZKZpNMF7aqDOPGJM5yXuUg7Atr00yDbQPmUJFO7pENP_d2i1DGZa6BL9KwjFkNn5IzAb0TXQiXs4ikq9lXZqhJjldjnKlgmxS56jmmgGMqcEzxiLxc91n0FTn-Sf0ambqmxGra4Yv5cqaGzakYoGaZFsnEFIhYjLa2hMFL63TqEq4j8gyXhMJ6GR4DcmZl1zTq4ONXNRXZRCDQYZcRHX8eEb0YiNwcBmrKIQkCpgvrcI0ot0eUsOvNuHm1PNUgdRoFUFTkEtPoIvJ03Yw9MZLO23mHNJkADDzhSUTu96t5PTkAZkQKj4iI0Tofzd64xdffQk1yyfGqV-j5arUjfv-ty7nz4P_In5DNT2_21IeDo_cPyfUMtzGgiCzdJhvtsrOPAB62-nGQAL8A00Vctg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Sulbactam+combined+with+tigecycline+improves+outcomes+in+patients+with+severe+multidrug-resistant+Acinetobacter+baumannii+pneumonia&rft.jtitle=BMC+infectious+diseases&rft.au=Yanling+Deng&rft.au=Lin+Chen&rft.au=Mingrui+Yue&rft.au=Xiaobo+Huang&rft.date=2022-10-21&rft.pub=BMC&rft.eissn=1471-2334&rft.volume=22&rft.issue=1&rft.spage=1&rft.epage=8&rft_id=info:doi/10.1186%2Fs12879-022-07778-5&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_480091803c82426cbeea2669efb1f05b |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2334&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2334&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2334&client=summon |